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Summary: 
 
Among 2,533 chronically hepatitis C-infected, treatment-naive persons in the Swiss 
Hepatitis C Cohort Study, 133 persons (5,3%) ever had a viral load ≤ 3,000 IU/ml. Part of 
these showed favourable disease courses, but 24 persons, all immunosuppressed, had 
cirrhosis. 
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Abstract: 
Background 
Hepatitis C virus (HCV) antigen testing is less expensive than quantitative RT-PCR but has lower sensitivity 
for very low viral loads (VLVL; HCV RNA ≤3,000 IU/ml). Currently the benefits of antigen testing for 
screening are discussed, but data on prevalence and outcomes of persons with VLVL are scarce. 
Methods 
We assessed prevalence and predictors of VLVL by logistic regression in treatment-naïve participants in the 
Swiss Hepatitis C Cohort Study. We analyzed if the last viral load after VLVL was low, compared cirrhosis 
and mortality in persons with and without VLVL, and evaluated the number of samples with VLVL that were 
reactive by antigen testing.  
Results 
We included 2,533 treatment-naïve persons with available quantitative HCV RNA testing results. Overall, 
133 persons (5.3%) had a VLVL. Age 18-40 years, female gender and HIV coinfection were associated with 
VLVL. Of 72 persons with a viral load available after VLVL, 14% had a VLVL and 17% had spontaneous viral 
clearance. The prevalence and incidence of cirrhosis and mortality were comparable in persons with and 
without VLVL; all 24 persons with VLVL and cirrhosis had excessive alcohol consumption or 
immunosuppression. Overall 33% of samples with VLVL were reactive by antigen testing.  
Conclusions 
The frequency of VLVL was low. Among the persons who would probably be missed by antigen screening, 
some had a favorable disease course, but some had immunosuppression and liver cirrhosis. The benefit of 
HCV antigen testing for screening may be limited by the risk of missing patients with severe liver disease. 
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Background 
Treatment-naïve persons with hepatitis C virus (HCV) infection usually have viral loads around 105-106 
IU/ml [1-3]. Viral loads <400,000-800,000 IU/ml have been referred to as “low viral loads” [4-7] and have 
been associated with higher proportions of spontaneous viral clearance [7,8], slower liver disease 
progression [9-11], improved response to interferon-based treatment [4,6], and more successful treatment 
of liver cancer [12]. In contrast, other studies have found no association between low viral loads and liver 
disease progression [2,13,14]. 
Viral loads <600 IU/ml [1] and <5,000 IU/ml [15] have been referred to as “very low viral loads” (VLVL). 
Recently, the frequency and prognostic value of VLVL have been discussed controversially in the context of 
HCV antigen testing [16,17]. HCV antigen testing can be a less expensive alternative to quantitative RT-PCR 
[14,16,18-21]. In resource-limited settings with high HCV prevalence, point-of-care antigen testing is 
discussed as a one-step procedure, without HCV antibody screening [21]. The sensitivity of HCV antigen 
testing to detect VLVL is low: in most studies, the only commercially available HCV antigen test had a 
detection limit of 3,000 IU/ml [17,22-27]; in a few studies the detection limit was 1,000 IU/ml [28-30].  
Little is known about the prevalence of VLVL among treatment-naïve persons. A study on laboratory 
samples with first-time HCV antibody positivity found viral loads ≤3,000 IU/ml in 3% (6/221) [24]. A meta-
analysis on viral loads in untreated persons had exclusion criteria such as viral loads <2,000 IU/ml and 
genotypes other than one; the results are therefore not relevant in our context [31]. Other studies were 
limited to settings where the majority of persons were treatment-experienced [1,15,29]; results are 
therefore not applicable to screening, where persons are treatment-naïve. More data are needed to better 
estimate the probability of missing HCV-positive persons with a VLVL at the time of screening, and to obtain 
information on their disease course. We therefore assessed the prevalence of VLVL in treatment-naïve 
persons, compared the characteristics and outcomes of persons with and without VLVL and analyzed the 
number of VLVL detected by antigen testing. 
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Methods 
We considered all persons enrolled in the Swiss Hepatitis C Cohort Study (SCCS) until September 10, 2017. 
The SCCS is a multicentre cohort study with continuous enrolment of anti-HCV positive persons aged >18 
years [32]. Study sites include five university hospitals, three additional large hospitals, and some affiliated 
centres. Enrolment started in the year 2000, and persons in any stage of disease are included. The 
standardized questionnaire includes data on demographic characteristics, HCV risk factors, genotype, HIV 
coinfection, organ transplantation and alcohol consumption. Clinical information is collected at enrolment 
and during yearly follow-up visits; at the same time plasma samples are collected and stored. The ethics 
committees of all eight participating hospitals granted ethical approval and all participants gave written 
informed consent. 
To avoid any treatment effects, we excluded all participants who were treated before enrolment into the 
SCCS. For participants who started their HCV treatment in the SCCS, we only considered viral loads before 
treatment start. In treatment-naïve participants, we considered all viral loads. We defined a VLVL as HCV 
RNA ≤3,000 IU/ml because most studies on HCV antigen testing had used this detection limit [17,22-27]. 
We performed five different analyses. First, we calculated the proportion of persons who ever had a VLVL 
among all persons with at least one available viral load. We evaluated if this proportion changed over time, 
considering the following time intervals after enrolment into the SCCS: ≥6 months to <3 years, ≥3 to <5.5 
and ≥5.5 to <8 years. We performed a chi-squared test for trend in proportions, and excluded the first six 
months from the analysis because spontaneous viral clearance is more frequent during this time period 
[7,33,34]. We compared the number of viral load tests in persons with and without VLVL. Since a VLVL may 
trigger more frequent testing, we compared the mean time between viral load tests before and after the 
first documented VLVL. We compared the proportion of people with a VLVL (among all patients with an 
available viral load) by type of quantitative RT-PCR assay used. 
Second, we assessed possible predictors of VLVL. We used univariable and multivariable logistic regression 
and included the following explanatory variables at cohort enrolment: gender, age (18-40, >40 years old), 
HCV genotype (1, 2, 3, 4; other genotypes were very rare and set to missing), history of intravenous drug 
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use (IVDU, yes/no), time elapsed between first documented HCV infection and enrolment (<2 years, 2 to 
<6, 6-10 and >10 years), alcohol consumption (no or light: <20 grams of alcohol per day; moderate: 20-40; 
excessive: >40; former: used to drink >40 grams of alcohol before enrolment), HIV coinfection, HBV 
coinfection, and presence of liver cirrhosis at enrolment.  
Third, we compared the prevalence and incidence of liver cirrhosis and all-cause mortality in persons with 
and without VLVL. We used univariable and multivariable logistic regression for prevalent cirrhosis, and Cox 
regression for incident cirrhosis and mortality. We included the same covariates as in the analysis of 
predictors of VLVL, but excluded “presence of liver cirrhosis at enrolment”. In persons with VLVL and 
cirrhosis, we extracted information from the patient charts on additional immunosuppressive conditions 
and treatments. 
We used multiple imputation by chained equations (MICE package for R; Van Buuren & Groothuis-
Oudshoorn 2011 [35]) to impute missing values in the covariates. Because the quality of the imputation can 
be improved by adding variables outside the analysis [36], we included if HCV treatment was started within 
the SCCS, if spontaneous HCV clearance occurred, the SCCS center enrolling the participant, and the 
respective outcome variable. We ran the model on 20 imputed datasets for each analysis and used Rubin’s 
rule to pool the estimates.  
Fourth, we analyzed the viral load trajectories after VLVL in persons with at least one viral load available ≥6 
months after the first VLVL. Depending on the last viral load value (negative, >0 to ≤3,000 IU/ml or above), 
we classified the persons as “undetectable”, “continuous VLVL“ or “rebound after VLVL”. We further 
classified persons with an undetectable last viral load as “confirmed spontaneous clearers” if they had two 
undetectable viral loads ≥6 months apart, and otherwise as “possible spontaneous clearers” [7]. 
We repeated the analyses with a viral load detection limit of 1,000 IU/ml instead of 3,000 IU/ml; for the 
fourth analysis, the sample size was too small.  
Fifth, in all participants with a frozen plasma sample available at the time of the VLVL, we performed 
antigen testing. We analyzed the antigen test results separately for VLVL ≤3,000 and VLVL ≤1,000 IU/ml, 
and classified them as reactive (>10 fmol/l), borderline reactive (3-10 fmol/l) and negative (<3 fmol/l).  
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As controls, we performed HCV antigen testing in 18 plasma samples with viral loads >3,000 – 50,000 
IU/ml, and in two plasma samples with undetectable HCV RNA. 
 
All the analyses were performed with R version 3.4.3 (R Core Team 2017, https://www.r-project.org).  
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Results 
We included 2,533 persons (46.8 % of 5,409 persons enrolled in the SCCS) who had HCV viral loads 
measured in the absence of therapy or before treatment start (Figure 1 and Table 1). Overall, 5.3% 
(133/2,533) of persons ever had a VLVL (Figure 1, Table 1), and 26 persons had a VLVL at least twice. Acute 
HCV infection before documentation of VLVL was excluded in 125 of the 133 persons (94%; HCV diagnosis 
≥6 months before VLVL), was unlikely in seven persons (5%; probable HCV infection ≥5 years before VLVL), 
and could not be excluded in one person (1%; active IVDU with negative HCV test 1.5 years before VLVL). 
The percentage of persons with a VLVL remained stable over time, ranging from 3.0 to 4.1% for the time 
intervals of 2.5 years (Table 1). Viral loads were measured more frequently in persons with than without a 
VLVL (mean number of measurements 4.2 vs. 2.3, p-value <0.001); the time interval between 
measurements remained similar before and after a VLVL (mean of 671 days before and 723 days after a 
VLVL, p=0.703). For different quantitative RT-PCR assays, the proportion of people with a VLVL (among all 
persons with a detectable viral load) was similar. 
Older age (>40 years), male gender, and being HIV-negative were associated with a lower probability of a 
VLVL (adjusted odds ratios 1.79, 95% CI 1.77-2.73; 1.50, 95% CI 1.00-2.24; and 2.20, 95% CI 1.24-3.92), 
while HCV genotype, history of IVDU, time between documented HCV infection and cohort enrolment, 
alcohol consumption, HBV coinfection, and cirrhosis at enrolment were not. Results were similar in the 
univariable analysis and if missing explanatory values were imputed by multiple imputation (Table 2), 
except for gender that was no longer associated. Viral load levels before the VLVL were comparable for 
persons with and without subsequent spontaneous clearance (median 233,615 vs 117,253 IU/ml, p=0.91; 
n=35 persons). 
Among the 133 persons with a VLVL, 18% (24 persons) had liver cirrhosis. Cirrhosis at enrolment, incident 
cirrhosis and mortality were similar in persons with and without VLVL (Table 3). All 24 persons with a VLVL 
and liver cirrhosis had at least one of the following conditions: HIV coinfection, organ transplantation, 
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(history of) excessive alcohol consumption, immunosuppressive treatment, diabetes mellitus, active IVDU 
with opioids, biliary cirrhosis or hepatitis B/D virus coinfection. 
Seventy-two of the 133 persons with a VLVL had at least one viral load available ≥6 months after their first 
VLVL. Of these, 14% (10/72) had a VLVL as their last viral load, 17% (12/72) spontaneously cleared the virus 
(eight with confirmed, four with possible clearance), and 69.4% (50/72) had a last viral load >3,000 IU/ml. 
Four of the 72 persons, all with active IVDU, were probably reinfected after viral clearance; however a 
detailed sequence analysis was not available. Among the 24 persons with a VLVL and liver cirrhosis, 12 
persons had at least one viral load available ≥6 months after their first VLVL. Of these, 42% (5/12) 
spontaneously cleared the virus or had a VLVL as last result (four after stop of excessive alcohol use, one 
after steroid treatment); 58% (7/12) had a viral load >3,000 as last result (six being immunosuppressed, one 
with excessive alcohol consumption and hepatitis B/D virus coinfection). 
When we repeated the analyses using ≤1,000 IU/ml to define a VLVL, results were similar. Overall 3.5% 
(88/2,533) of the participants ever had a VLVL ≤1,000 IU/ml, and the percentage of persons who ever had a 
VLVL ≤1,000 IU/ml remained stable over time (2.1% to 2.8% across the three time intervals). Young age (18-
40 years), excessive alcohol consumption and absence of IVDU were associated with VLVL ≤1,000 (adjusted 
odds ratios 2.15, 95% CI 1.26-3.67; 1.92, 95% CI 1.03-3.57; and 1.94, 95% CI 1.10-3.42), while the other 
covariates were not. In the univariable analysis, the covariates associated with VLVL ≤1,000 were young age 
and excessive alcohol use (compared to no or light drinking). There were no differences between persons 
with and without a VLVL ≤1,000 for prevalence of cirrhosis at enrolment, incidence of cirrhosis and 
mortality. 
Among the 133 persons with a VLVL, 90 persons had the VLVL documented at the yearly SCCS visit and 43 
during another visit when no plasma sample was stored. For one person, the frozen plasma sample was 
unavailable. For the remaining 89 persons, HCV antigen testing for VLVL ≤3,000 IU/ml was reactive in 24% 
(21/89), borderline reactive in 9% (8/89) and negative in 67% (60/89) persons. Among the 89 persons, 54 
persons had a VLVL ≤1,000 IU/ml, with HCV antigen testing reactive in 20% (11/54), borderline reactive in 
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4% (2/54) and negative in 76% (41/54) of persons. For the 24 persons with a VLVL and cirrhosis, plasma 
samples were available in 13 persons; HCV antigen testing was reactive in four, borderline reactive in one 
and negative in eight persons. 
The hepatitis C antigen test was reactive in all control samples with viral loads >3,000 – 50,000 IU/ml, and 
negative in those with undetectable viral loads. 
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Discussion 
Using real-life data from the SCCS, we could show that the proportion of treatment-naïve persons with a 
VLVL was low. Overall 5.3% of persons ever had a VLVL ≤3,000 IU/ml, and during shorter time intervals of 
2.5 years this proportion dropped to 3.0-4.3%. This is in line with a previous study which showed a 
prevalence of 3% VLVL in Switzerland [24] and with the Georgian HCV Elimination Program where the 
proportion of viral loads <1,500 IU/ml was 1.2% [37]. In other studies, the prevalence of VLVL had been 
evaluated among persons who were mostly treatment-experienced, rendering their results not applicable 
to the context of screening. Despite these differences in study design, the frequency of VLVL was often 
similar. For example, in two studies including persons with a relapse after HCV treatment, a VLVL ≤1,000 
IU/ml occurred in 4% [29], and a VLVL <5,000 IU/ml in 16% of persons [15]. In evaluations of blood samples 
of mostly treatment-experienced persons, a VLVL <600 IU/ml occurred in 2% [1], and a VLVL <1,000 in 3.5% 
of persons [29]. 
In our study, some aspects were favorable in persons who had a VLVL. Firstly, while HCV viral load values 
usually increase with longer follow-up duration [38,39], the percentage of persons with a VLVL remained 
constant over a period of >8 years (Table 1). Second, although spontaneous clearance is rare during chronic 
infection [7,34], we found that a relatively large proportion of persons spontaneously cleared their HCV 
infection: among the 72 persons with a viral load determination performed after their first VLVL, eight 
(11%) were confirmed and four (5.5%) were possible viral clearers. Four active IVDU with confirmed or 
possible viral clearance and a subsequent detectable viral load were probably reinfected. It is possible that 
more persons cleared the virus among the 61 persons without viral load tests after the VLVL. Interestingly, 
young age, which was associated with VLVL ≤3,000 and VLVL ≤1,000 in our study, had previously been 
described as a predictor of spontaneous clearance [7,8,34], and low viral loads have been reported to 
precede spontaneous clearance [7,8]. 
Although the prevalence and incidence of cirrhosis were comparable in persons with and without VLVL in 
our study, a proportion of 18% (24/133) cirrhosis in persons with VLVL is worrisome; all of these had 
excessive alcohol consumption or immunosuppression. If population-based screening for HCV is performed 
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with an HCV antibody test followed by HCV antigen testing, or with HCV antigen testing alone, the chronic 
HCV infection of these persons may be missed. This problem would not occur in the case of etiological 
screening of an otherwise unexplained liver disease, where persons who are HCV antibody positive would 
in general undergo diagnostic workup. However, the likelihood and negative consequences of missing a 
person with VLVL and cirrhosis during a general population-based screening may be reduced for two 
reasons: First, point-of-care assays for HCV core antigen are in development, and they may have a lower 
limit of detection compared to the currently available assay [18]. Second, in some persons with a VLVL and 
cirrhosis, factors other than HCV were likely predominant in the pathogenesis of the cirrhosis. Indeed, some 
persons spontaneously cleared their HCV after excessive alcohol consumption or after steroid therapy had 
been stopped. The frequency of alcohol consumption and immunosuppression including HIV coinfection in 
our study may mirror the HCV epidemic in Switzerland, which is characterized by a large proportion of IVDU 
(with increased HIV coinfection and potentially increased alcohol consumption) [40], and by an ageing 
population with age-related comorbidities [41,42,43]. The frequency of VLVL and cirrhosis may therefore 
be different in other settings. We had too few cases with HBV coinfection and only incomplete information 
on host genetics for meaningful analyses. Similar to previous studies [17,22-24,27,28], we found no 
difference in the prevalence of VLVL by HCV genotype.  
Usually persons with immunosuppression have high HCV viral loads [13,38,39,44]. The occurrence of a VLVL 
in immunosuppressed and HIV coinfected patients is therefore surprising. We have at present no 
explanations for this counterintuitive observation. 
Our study has a number of strengths and limitations. All persons came from the multicentric SCCS, which 
includes a large number of patients, some followed up for 16 years [32]. Despite its large size, the SCCS only 
includes about one tenth of the estimated 40,000 HCV-infected persons in Switzerland [41], and persons in 
the SCCS may be in a more advanced stage of liver disease [32]. Nevertheless, patient characteristics are 
similar to the national notification data from the Federal Office of Public Health [32,41,42]. The high 
frequency of viral load tests in some persons may have led to a higher probability of detecting a VLVL. 
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Indeed, persons with a VLVL had more viral loads recorded than those without. However, the detection of a 
VLVL did not lead to an increase in testing. For persons with HIV coinfection, the degree of 
immunosuppression and the effect of antiretroviral treatment could not be taken into account. It was not 
always clear whether immunosuppressive treatment was still ongoing. The number of deaths was likely 
underestimated because some of the patients lost to follow-up may have died. Some of the covariates had 
missing values that reduced the number of people who could be included in the multivariable analysis, but 
results were similar when we imputed the missing values by multiple imputation. Information on IFNL3/4 
polymorphisms was available for too few persons with VLVL to allow for meaningful analyses.   
In conclusion, HCV antigen testing has been shown to perform well well in different geographic locations 
[16,17,20,21,37], but the low sensitivity for VLVL remains problematic. We show that VLVL that might not 
be detected by antigen testing are low: VLVL occured in 5.3% of treatment-naïve persons overall, and 
numbers will likely be lower for screening, which is based on a single test. In addition, some persons with 
VLVL had favourable disease courses. Since we found VLVL among persons with immunosuppression and 
liver cirrhosis, the benefit of HCV antigen testing for screening may be limited by the risk of missing patients 
with severe liver disease. 
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Figure Legend 
Figure 1: Flowchart of the patient selection process in the Swiss Hepatitis C Cohort Study (SCCS) 
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Table 1: Frequency of very low viral loads (VLVL) among persons in the Swiss Hepatitis C Cohort Study 
  
 Persons with at least one VLVL value, among all 
participants with ≥ 1 HCV RNA value(s) 
Total                       133/2,533 (5.3 %) 
Time since enrolment  
     < 6 months                        50/1,760 (2.8 %) 
     ≥ 6 months to < 3 years                        37/1,237 (3.0 %) 
     ≥ 3 years to < 5,5 years                          27/662 (4.1 %) 
     ≥ 5,5 years to < 8 years                          17/399 (4.3 %) 
     ≥ 8 years                          18/442 (4.1 %) 
 
VLVL = detectable HCV RNA ≤ 3,000 IU/ml 
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Table 2: Predictors of very low viral loads (VLVL) in the Swiss Hepatitis C Cohort Study 
 No of persons 
(N=2,533) 
Ever 
VLVL 
(N=133) 
Univariable OR  
for VLVL  
 
Multivariable 
OR for VLVL 
(N = 2,166) 
Multiple 
imputation OR 
Gender   (N = 2,532)   
    Female 1,016 61 1 1 1 
    Male 1,516 72 0.78 [0.55;1.11] 0.67 [0.45;1.00] 0.72 [0.50;1.04] 
Age (years)   (N = 2,527)   
    18-≤40 1,064 71 1 1 1 
    ≥41 1,463 62 0.62 [0.44;0.88] 0.56 [0.37;0.85] 0.58 [0.40;0.86] 
Genotype   (N = 2,244)   
     1 1,185 61 1 1 1 
     2  181 11 1.19 [0.62;2.31] 1.33 [0.66;2.69] 1.22 [0.61;2.45] 
     3 604 25 0.80 [0.49;1.28] 0.77 [0.47;1.27] 0.76 [0.46;1.25] 
     4 274 18 1.30 [0.75;2.23] 1.20 [0.68;2.12] 1.29 [0.74;2.26] 
IVDU   (N = 2,508)   
    No 972 53 1 1 1 
    Yes 1,536 79 0.94 [0.66;1.34] 0.70 [0.44;1.12] 0.77 [0.51;1.18] 
Time (years)   (N = 2,485)   
    0-2 1,124 67 1 1 1 
   >2-6 581 27 0.77 [0.49;1.22] 0.74 [0.45;1.23] 0.69 [0.43;1.11] 
   >6-10 389 16 0.68 [0.39;1.18] 0.75 [0.41;1.36] 0.61 [0.34;1.08] 
   >10 391 19 0.81 [0.48;1.36] 1.10 [0.62;1.95] 0.88 [0.52;1.50] 
Alcohol 
consumption 
  (N = 2,520)   
    No or light 1,323 64 1 1 1 
    Moderate 398 20 1.04 [0.62;1.74] 1.25 [0.71;2.18] 1.18 [0.69;1.99] 
    Excessive 633 40 1.33 [0.88;1.99] 1.46 [0.89;2.38] 1.48 [0.95;2.31] 
    Former excess. 166 9 1.13 [0.55;2.31] 0.85 [0.33;2.21] 1.32 [0.62;2.77] 
HIV coinfection   (N = 2,533)   
    Yes 212 20 1 1 1 
    No 2,321 113 0.49 [0.30;0.81] 0.45 [0.25;0.81] 0.47 [0.28;0.81] 
HBV coinfection   (N = 2,533)   
    Yes 47 5 1  1 
    No 2,486 128 0.46 [0.18;1.17] 0.94 [0.22;4.06] 0.50 [0.19;1.33] 
Cirrhosis   (N = 2,506)   
    Yes 236 13 1  1 
    No 2,270 119 0.95 [0.53;1.71] 0.99 [0.48;2.06] 0.87 [0.47;1.63] 
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VLVL = detectable HCV RNA ≤ 3,000 IU/ml. IVDU = (history of) intravenous drug use. Time (years) = time 
elapsed between first documentation of HCV infection and enrollment. Alcohol consumption: no or light: 0-
<20 grams of alcohol per day, moderate: 20-40, excessive: >40, former: >40 before enrolment. 
Numbers do not always sum up to the total number of persons, due to missing values in covariates.   
Odds ratios (OR) with 95% confidence intervals, based on logistic regression.  
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Table 3: Cirrhosis at enrolment, incident cirrhosis and mortality in persons with compared to persons 
without a very low viral load value, in the Swiss Hepatitis C Cohort Study 
 
 
       Univariable         Multivariable* 
Cirrhosis at enrolment OR 0.95 [0.53;1.71] OR 0.99 [0.47;2.08] 
Incident cirrhosis HR 0.77 [0.38;1.56] HR 0.63 [0.28;1.44] 
Mortality HR 0.73 [0.39;1.37] HR 0.46 [0.20;1.06] 
Very low viral load = detectable HCV RNA ≤ 3,000 IU/ml. 
OR: odds ratio from logistic regression; HR: hazard ratio from Cox regression. 
* The inclusion of covariates is explained in the methods section.  
 
D
ow
nloaded from
 https://academ
ic.oup.com
/cid/advance-article-abstract/doi/10.1093/cid/ciz270/5426964 by U
niversitaetsbibliothek Bern user on 08 April 2019
